Pulmonology Coding Alert

You Be the Coder:

Don't Confuse 96401 with 96372 for Xolair Administration

Question:We just gave our first Xolair injection recently. The patient had the drug shipped to us, so we are not billing for the drug -- just the administration of it. How should I report it? New Jersey SubscriberAnswer:You are right, in the sense that the physician reports the administration only. Since the physician/practice doesn't incur the cost of the drug, the physician/practice should not be reimbursed for this. On the other hand, the administration of the drug does represent an expense to the physician (for the office, staff and equipment), and therefore, you can report it. Red flag: There has been much controversy over the correct code to select for Xolair administration.  Although categorized as a monoclonal antibody (which would lend toward reporting 96401, Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic), most payers require reporting CPT 96372 (Therapeutic, prophylactic, or diagnostic injection [specify substance or drug); subcutaneous or intramuscular]) due to the [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Pulmonology Coding Alert

View All